Compare Abbott Laboratories (ABT) vs Enbridge Inc (ENB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Enbridge Inc — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Enbridge Inc trades at $55.1 (market cap $120.14B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Enbridge Inc pays the higher dividend (5.11%). Which is the better fit depends on your goals.
| ABT | ENB | |
|---|---|---|
Market Cap | $166.94B | $120.14B |
Sector | Health | Energy |
52-Week High | $136.62 | $58.04 |
52-Week Low | $82.57 | $43.79 |
Enterprise Value | $193.69B | $200.94B |
Dividend Yield | 2.63% | 5.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Enbridge (ENB) trades at $55.05, up 1.79% for the day, with a bearish technical signal from moving averages. The company reported strong revenue growth to $65.19B in 2025 and a net income margin of 10%, though it missed Q3 2025 EPS estimates. Recent news highlights include a dividend payment of $0.97 and upcoming Q2 2026 earnings on July 31, 2026. Analyst consensus is split evenly between Buy and Hold ratings.
Outlook remains mixed with solid cash flow from operations supporting dividends, but debt levels have risen to 48.81% of assets. Key risks include energy market volatility and execution of growth projects. The stock offers a high yield but faces near-term technical pressure and valuation concerns at a P/E of 25.73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
